| A compound L1196M/G1202R ALK mutation in a patient with ALK-positive lung cancer with acquired resistance to brigatinib also confers primary resistance to lorlatinib GG Sharma, D Cortinovis, F Agustoni, G Arosio, M Villa, N Cordani, ... Journal of Thoracic Oncology 14 (11), e257-e259, 2019 | 29 | 2019 |
| Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma G Arosio, GG Sharma, M Villa, M Mauri, I Crespiatico, D Fontana, ... Cancers 13 (17), 4422, 2021 | 13 | 2021 |
| New advances in liquid biopsy technologies for anaplastic lymphoma kinase (ALK)—Positive cancer M Villa, GG Sharma, C Manfroni, D Cortinovis, L Mologni Cancers 13 (20), 5149, 2021 | 7 | 2021 |
| Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering V Crippa, F Malighetti, M Villa, A Graudenzi, R Piazza, L Mologni, ... Computers in Biology and Medicine 162, 107064, 2023 | 4 | 2023 |
| Age-related dna damage response (ddr) in hematopoietic stem cells from chronic myeloid leukaemia patients who attempted tki discontinuation C Manfroni, G Arosio, M Mauri, M Villa, G Giudici, S Bombelli, B Manghisi, ... Haematologica 106 (10), 83-83, 2021 | 2 | 2021 |
| DNA damage response (DDR) is associated with treatment-free remission in chronic myeloid leukemia patients F Malighetti, G Arosio, C Manfroni, M Mauri, M Villa, B Manghisi, E Inzoli, ... HemaSphere 7 (3), e852, 2023 | 1 | 2023 |
| Effects of CD24 Don't Eat Me Signal Blockade in Combination with Anti-CD47 and Rituximab in Mantle-Cell Lymphoma A Aroldi, M Mauri, M Villa, F Malighetti, F Cocito, C Voena, R Chiarle, ... Blood 140 (Supplement 1), 3136-3138, 2022 | 1 | 2022 |
| Abstract P1-13-21: Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells N Cordani, L Mologni, R Piazza, V Cogliati, F Pepe, S Capici, CD Bella, ... Cancer Research 83 (5_Supplement), P1-13-21-P1-13-21, 2023 | | 2023 |
| PB1748: DIFFERENTIAL IRON HOMEOSTASIS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN VITRO MODELS MM Capelletti, M D’Angiò, G Fazio, P Sara, M Villa, A Piperno, C Giovanni HemaSphere 6, 1629-1630, 2022 | | 2022 |
| Novel ALK mutations in EML4:: ALK+ NSCLC resistant to TKIs identified by liquid biopsy M Villa, F Malighetti, G Sharma, G Arosio, E Sala, C Manfroni, D Fontana, ... | | 2022 |
| Synergistic drug combinations prevent drug resistance in anaplastic large cell lymphoma preclinical models GG Sharma, G Arosio, M Villa, M Mauri, M Zappa, V Magistroni, M Ceccon, ... Cancer Research 81 (13_Supplement), 1113-1113, 2021 | | 2021 |
| Characterization of potential co-drivers of pathogenesis in ALK positive ALCL L Mologni, GG Sharma, M Villa, M Mauri, G Arosio, C Lobello, H Larose, ... Cancer Research 80 (16_Supplement), 4715-4715, 2020 | | 2020 |
